{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:52:13Z","timestamp":1777866733624,"version":"3.51.4"},"reference-count":0,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood"],"published-print":{"date-parts":[[2004,11,15]]},"DOI":"10.1182\/blood-2004-04-1323","type":"journal-article","created":{"date-parts":[[2004,7,29]],"date-time":"2004-07-29T20:27:15Z","timestamp":1091132835000},"page":"3064-3071","source":"Crossref","is-referenced-by-count":482,"title":["The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group"],"prefix":"10.1182","volume":"104","author":[{"given":"R.","family":"Forstpointner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","container-title":["Blood"],"original-title":[],"language":"en","deposited":{"date-parts":[[2011,8,22]],"date-time":"2011-08-22T10:34:06Z","timestamp":1314009246000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.bloodjournal.org\/cgi\/doi\/10.1182\/blood-2004-04-1323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,15]]},"references-count":0,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-04-1323","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,15]]}}}